Cerulean Pharma

Cerulean: Leadership in Nanoparticle-Drug Conjugates.

Launch date

2006

Market cap

Enterprise valuation

Cambridge Massachusetts (HQ)

Revenues, earnings & profits over time

EUR	2015
R&D budget	24.0m

Source: Dealroom estimates

Date	Investors	Amount	Round
May 2007	Lux Capital Polaris Partners Venrock	$12.1m	Series A
Jan 2008	Bessemer Venture Partners	$8.1m	Series B
Jul 2009	Bessemer Venture Partners Lux Capital Polaris Partners Venrock	$10.0m	Series B
Oct 2010	Lilly Ventures	$1.5m	Debt
Nov 2010	Lux Capital Polaris Partners Venrock Lilly Ventures	$24.0m	Series C
Dec 2011	Bessemer Venture Partners	$15.0m	Series D
Dec 2012	Lux Capital Polaris Partners Venrock Lilly Ventures CVF	$13.0m	Growth Equity VC
Apr 2014	N/A	N/A	IPO
Jul 2017	Dare Bioscience	N/A	Acquisition
Total Funding		€74.7m

Financials